Nirsevimab 87.02% Effective Against Infant RSV Hospitalization at 300 Days

The significance here lies less in the efficacy figure than in the setting: this is described as China's first systematic real-world look at nirsevimab protection past 180 days in Chinese infants, extending the evidence base beyond the trial populations that typically underpin approval decisions. The data are preliminary and conference-presented, so they carry less weight than peer-reviewed findings, but they matter for how passive immunization for RSV is framed in a large infant population. The open question is whether longer-duration protection holds up under fuller scrutiny and whether such real-world reporting shapes how the antibody is positioned relative to maternal vaccination strategies.